Q3 Report 2019

Thanks to the progress made, we are on track for potential new drug approvals as of the second half of 2020, and we are very excited by the prospect of bringing filgotinib as a new treatment option to RA patients.

Financial highlights

Group revenues

€752.5 million

At a glance

Cash position

€5599.8 million

At a glance

Letter from the management

Gilead and we strongly believe that this collaboration will provide an accelerated path to advance our pipeline, and thus provide the opportunity to fast track our mission to bring innovation to patients worldwide.
Onno van de Stolpe, CEO
Letter from the management